XHKG
3839
Market cap243mUSD
Oct 09, Last price
7.92HKD
1D
-0.38%
1Q
-16.63%
Jan 2017
256.76%
IPO
101.53%
Name
Chia Tai Enterprises International Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chia Tai Enterprises International Limited (CTEI) is a global entity primarily involved in the production and distribution of chlortetracycline (CTC) and its associated derivatives. The company's business activities span Mainland China, the Asia Pacific region, the Americas, Europe, and other international markets, and are organized into two principal divisions: Biochemical and Industrial. The Biochemical segment concentrates on the formulation and commercialization of CTC premix and CTC hydrochloride products. These substances function as crucial feed additives for livestock, designed to foster growth, ward off or alleviate animal ailments, and enhance feed efficiency, marketed under the "Shihao" and "Citifac" brand names. In contrast, the Industrial segment encompasses the sale, rental, and maintenance services for various Caterpillar heavy equipment, including excavators, power generators, bulldozers, and compactors, alongside their corresponding spare parts. This division also undertakes the manufacturing and supply of carburetors and diverse automotive components for vehicle and motorcycle producers. Established in 1987, CTEI's headquarters are located in Central, Hong Kong, and it operates as a subsidiary of Charoen Pokphand Foods Public Company Limited.
Key people
Non-Executive Chairman of the Board · since 2014
Thanakorn Seriburi
Executive Director, Chief Executive Officer - Industrial Division · since 2014
Nopadol Chiaravanont
Executive Director · since 2014
Chawalit Na Muangtoun
Executive Director · since 2019
Thirayut Phityaisarakul
Executive Director, Chief Executive Officer - Biochemical Division · since 2014
Wing Yuen Lau
Company Secretary · since 2022
Non-Executive Director · since 2015
Independent Non-executive Director · since 2014
Marn Kay Cheung
Non-Executive Independent Director · since 2024
Independent Non-executive Director · since 2014
Surasak Rounroengrom
Independent Non-executive Director · since 2014
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||